Janus Henderson Group
RLMD icon

Janus Henderson Group’s Relmada Therapeutics RLMD Stock Holding History

Janus Henderson Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.9M Buy
11,063,862
+3,793,862
+52% +$17.9M 0.04% 331
2025
Q4 		$35M Buy
+7,270,000
New +$24.4M 0.02% 483
2022
Q4 		– Sell
-5,937
Closed -$220K – 2495
2022
Q3 		$220K Buy
+5,937
New +$164K ﹤0.01% 2360

Other funds holding RLMD

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Janus Henderson Group's RLMD Position: Q1 2026 in Review

Janus Henderson Group increased its Relmada Therapeutics (RLMD) stake by 52% in Q1 2026, buying an estimated $17.9M and bringing the position to 11,063,862 shares worth $76.9M. The position accounts for 0.04% of the portfolio, ranked #331.

Janus Henderson Group first reported a position in RLMD in Q3 2022 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Janus Henderson Group held 11,063,862 shares of Relmada Therapeutics worth $76.9M as of Q1 2026.
  • Janus Henderson Group bought 3,793,862 Relmada Therapeutics shares in Q1 2026, an estimated $17.9M.
  • Relmada Therapeutics made up 0.04% of Janus Henderson Group's portfolio in Q1 2026, its #331 holding.
  • Janus Henderson Group first reported a position in Relmada Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.